4-HO-MPMI
 |
|
| Identifiers | |
|---|---|
|
|
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C14H17N2O |
| Molar mass | 229.297 g/mol |
| 3D model (Jmol) | |
|
|
|
|
  (what is this?) (verify) |
|
4-HO-MPMI (also known as 4-Hydroxy-N-methyl-(α,N-trimethylene)tryptamine or lucigenol) is a tryptamine derivative that is a psychedelic drug. It was developed by the team led by David Nichols from Purdue University in the late 1990s. This compound produces hallucinogen-appropriate responding in animal tests with a similar potency to the amphetamine-derived psychedelic DOI, and has two enantiomers, with only the (R)-enantiomer being active.[1]
The binding affinity for 5-HT2A receptor is 13 ± 2 nM (Ki [125I]DOI). It is reported at doses starting at 0.5 mg and 1.0-1.5 mg seem to be psychedelic doses. The duration it is reported between six and eight hours. The effects, still not too documented, are OEV/CEV, sedation and anxiety.[2][unreliable source?]
See also[edit]
References[edit]
- ^ Gerasimov M, Marona-Lewicka D, Kurrasch-Orbaugh DM, Qandil AM, Nichols DE (1999). "Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain". Journal of Medicinal Chemistry. 42 (20): 4257–4263. doi:10.1021/jm990325u. PMID 10514296.
- ^ http://www.hipforums.com/newforums/showthread.php?t=315326
